SCHEDULE 13G/A 0001062993-22-003816 0001601364 XXXXXXXX LIVE 1 Common Stock, par value $0.00001 per share 02/13/2026 0001501796 Aura Biosciences, Inc. 05153U107 80 Guest Street Boston MA 2135 Rule 13d-1(d) Advent Life Sciences LLP X0 0 2023857 0 2023857 2023857 N 3.258 PN By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein. Advent Life Sciences Fund I LP X0 0 2023857 0 2023857 2023857 N 3.258 PN By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein. Rajesh Parekh, Ph.D. X0 0 2023857 48000 2071857 2071857 N 3.335 IN By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein. Advent Life Sciences Fund III LP X0 0 2023857 0 2023857 2023857 N 3.258 PN By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein. ALS III Carry and Co-Invest LP X0 0 2023857 0 2023857 2023857 N 3.258 PN By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein. Advent-Harrington Impact Fund LP X0 0 2023857 0 2023857 2023857 N 3.258 PN By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein. Aura Biosciences, Inc. 80 Guest Street, Boston, MASSACHUSETTS 2135 Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP and Rajesh Parekh, Ph.D. 27 Fitzroy Square, London, United Kingdom W1T 6ES Citizenship: Advent Life Sciences LLP ("Advent") is a limited liability partnership organized under the laws of the United Kingdom. Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, and Advent-Harrington Impact Fund LP (collectively, the "Advent Funds") are limited partnerships organized under the laws of the United Kingdom. Dr. Parekh is a citizen of the United Kingdom. Y Advent and the Advent Funds may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. Dr. Parekh who is a general partner of each of Advent and the Advent Funds, formerly served as a director of the Company and has options to purchase a total of 48,000 shares of Common Stock. By virtue of the relationships set forth herein, Dr. Parekh may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein. Advent Life Sciences LLP and the Advent Funds 3.258%; Dr. Parekh 3.335%. 0 By virtue of the relationships set forth herein, Advent and the Advent Funds may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. Dr. Parekh who is a general partner of Advent and each of the Advent Funds, formerly served as a director of the Company and has options to purchase a total of 48,000 shares of Common Stock. By virtue of the relationships set forth herein, Dr. Parekh may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein. Advent Life Sciences LLP and the Advent Funds 0% and Dr. Parekh 0.07727%, By virtue of the relationships set forth herein, Advent and the Advent Funds may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. Dr. Parekh who is a general partner of each of Advent and the Advent Funds, formerly served as a director of the Company and has options to purchase a total of 48,000 shares of Common Stock. By virtue of the relationships set forth herein, Dr. Parekh may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein. N Y Y Y Y Y Y Agreement Regarding the Joint Filing of Schedule 13G dated February 11, 2022 (as filed by the Reporting Persons on Schedule 13G on February 14, 2022). Advent Life Sciences LLP /s/Rajesh Parekh, Ph.D. 02/13/2026 Advent Life Sciences Fund I LP /s/Rajesh Parekh, Ph.D. 02/13/2026 Rajesh Parekh, Ph.D. /s/Rajesh Parekh, Ph.D. 02/13/2026 Advent Life Sciences Fund III LP /s/Rajesh Parekh, Ph.D. 02/13/2026 ALS III Carry and Co-Invest LP /s/Rajesh Parekh, Ph.D. 02/13/2026 Advent-Harrington Impact Fund LP /s/Rajesh Parekh, Ph.D. 02/13/2026 See comments re: reporting persons and signature information.